Camlin Fine Sciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 29, 2025, 8:23 pm

Quick Insight

Camlin Fine Sciences Ltd currently trades at ₹230 with a Market Cap of ₹4,317 Cr, reflecting a high P/E ratio of 114, significantly above the sector average of around 30-40x. The company's ROE stands at 15.0%, slightly below the industry norm of 18-20%, while ROCE at 11.0% is also lower compared to peers at 15-18%. With a Net Profit of -₹158 Cr, Camlin faces profitability challenges, evident in its low OPM of 4%. On the positive side, the company boasts healthy reserves of ₹883 Cr and a moderate P/BV ratio of 1.83x, indicating decent asset backing for shareholders.

However, Camlin's high borrowing levels of ₹681 Cr raise concerns about its financial leverage, especially with an ICR of 1.48x, below the comfort zone of 2x. Additionally, the CCC of 143 days indicates inefficiencies in working capital management, impacting liquidity. Going forward, improving operational efficiency to boost margins and reducing reliance on borrowings could enhance the company's financial health and investor confidence. While the stock may appear undervalued based on book value, investors should closely monitor the company's profitability and debt levels as key indicators of future performance in the volatile specialty chemicals sector.

In conclusion, despite facing challenges in profitability and leverage, Camlin Fine Sciences Ltd has the potential to strengthen its position through strategic operational improvements and prudent financial management. Investors should exercise caution and monitor the company's progress in addressing these key areas to make informed investment decisions.

Competitors of Camlin Fine Sciences Ltd

All Competitor Stocks of Camlin Fine Sciences Ltd

Quarterly Result

Last Updated: August 20, 2025, 12:30 pm

Below is a detailed analysis of the quarterly data for Camlin Fine Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 424.00 Cr.. The value appears to be declining and may need further review. It has decreased from 437.00 Cr. (Mar 2025) to 424.00 Cr., marking a decrease of 13.00 Cr..
• For Expenses, as of Jun 2025, the value is 405.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 378.00 Cr. (Mar 2025) to 405.00 Cr., marking an increase of 27.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 59.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 40.00 Cr..
• For OPM %, as of Jun 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 4.00%, marking a decrease of 10.00%.
• For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from -17.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 20.00 Cr..
• For Interest, as of Jun 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
• For Depreciation, as of Jun 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2025) to -11.00 Cr., marking a decrease of 19.00 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 99.00% (Mar 2025) to 0.00%, marking a decrease of 99.00%.
• For Net Profit, as of Jun 2025, the value is -11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2025) to -11.00 Cr., marking a decrease of 11.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -0.53. The value appears to be declining and may need further review. It has decreased from -0.04 (Mar 2025) to -0.53, marking a decrease of 0.49.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:32 pm

Growth

Last Updated: September 5, 2025, 1:30 am

Balance Sheet

Last Updated: July 25, 2025, 3:27 pm

Below is a detailed analysis of the balance sheet data for Camlin Fine Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Mar 2024) to 19.00 Cr., marking an increase of 2.00 Cr..
• For Reserves, as of Mar 2025, the value is 883.00 Cr.. The value appears strong and on an upward trend. It has increased from 848.00 Cr. (Mar 2024) to 883.00 Cr., marking an increase of 35.00 Cr..
• For Borrowings, as of Mar 2025, the value is 681.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 683.00 Cr. (Mar 2024) to 681.00 Cr., marking a decrease of 2.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 454.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 424.00 Cr. (Mar 2024) to 454.00 Cr., marking an increase of 30.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,037.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,972.00 Cr. (Mar 2024) to 2,037.00 Cr., marking an increase of 65.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 704.00 Cr.. The value appears to be declining and may need further review. It has decreased from 816.00 Cr. (Mar 2024) to 704.00 Cr., marking a decrease of 112.00 Cr..
• For CWIP, as of Mar 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 46.00 Cr. (Mar 2024) to 10.00 Cr., marking a decrease of 36.00 Cr..
• For Investments, as of Mar 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 53.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,262.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,102.00 Cr. (Mar 2024) to 1,262.00 Cr., marking an increase of 160.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,037.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,972.00 Cr. (Mar 2024) to 2,037.00 Cr., marking an increase of 65.00 Cr..

Notably, the Reserves (883.00 Cr.) exceed the Borrowings (681.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Camlin Fine Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 24, the value is -5.58. This value is below the healthy minimum of 5. It has decreased from 3.45 (Mar 23) to -5.58, marking a decrease of 9.03.
• For Diluted EPS (Rs.), as of Mar 24, the value is -5.50. This value is below the healthy minimum of 5. It has decreased from 3.41 (Mar 23) to -5.50, marking a decrease of 8.91.
• For Cash EPS (Rs.), as of Mar 24, the value is -1.57. This value is below the healthy minimum of 3. It has decreased from 6.51 (Mar 23) to -1.57, marking a decrease of 8.08.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 48.29. It has increased from 48.18 (Mar 23) to 48.29, marking an increase of 0.11.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 50.97. It has decreased from 52.25 (Mar 23) to 50.97, marking a decrease of 1.28.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 96.32. It has decreased from 107.04 (Mar 23) to 96.32, marking a decrease of 10.72.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 5.34. This value is within the healthy range. It has decreased from 13.44 (Mar 23) to 5.34, marking a decrease of 8.10.
• For PBIT / Share (Rs.), as of Mar 24, the value is 0.64. This value is within the healthy range. It has decreased from 9.46 (Mar 23) to 0.64, marking a decrease of 8.82.
• For PBT / Share (Rs.), as of Mar 24, the value is -5.93. This value is below the healthy minimum of 0. It has decreased from 5.12 (Mar 23) to -5.93, marking a decrease of 11.05.
• For Net Profit / Share (Rs.), as of Mar 24, the value is -6.26. This value is below the healthy minimum of 2. It has decreased from 2.53 (Mar 23) to -6.26, marking a decrease of 8.79.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -5.54. This value is below the healthy minimum of 2. It has decreased from 3.32 (Mar 23) to -5.54, marking a decrease of 8.86.
• For PBDIT Margin (%), as of Mar 24, the value is 5.54. This value is below the healthy minimum of 10. It has decreased from 12.55 (Mar 23) to 5.54, marking a decrease of 7.01.
• For PBIT Margin (%), as of Mar 24, the value is 0.67. This value is below the healthy minimum of 10. It has decreased from 8.83 (Mar 23) to 0.67, marking a decrease of 8.16.
• For PBT Margin (%), as of Mar 24, the value is -6.15. This value is below the healthy minimum of 10. It has decreased from 4.77 (Mar 23) to -6.15, marking a decrease of 10.92.
• For Net Profit Margin (%), as of Mar 24, the value is -6.50. This value is below the healthy minimum of 5. It has decreased from 2.36 (Mar 23) to -6.50, marking a decrease of 8.86.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is -5.75. This value is below the healthy minimum of 8. It has decreased from 3.09 (Mar 23) to -5.75, marking a decrease of 8.84.
• For Return on Networth / Equity (%), as of Mar 24, the value is -11.35. This value is below the healthy minimum of 15. It has decreased from 6.92 (Mar 23) to -11.35, marking a decrease of 18.27.
• For Return on Capital Employeed (%), as of Mar 24, the value is 0.89. This value is below the healthy minimum of 10. It has decreased from 11.72 (Mar 23) to 0.89, marking a decrease of 10.83.
• For Return On Assets (%), as of Mar 24, the value is -4.75. This value is below the healthy minimum of 5. It has decreased from 2.52 (Mar 23) to -4.75, marking a decrease of 7.27.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.40. This value is within the healthy range. It has decreased from 0.54 (Mar 23) to 0.40, marking a decrease of 0.14.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.80. This value is within the healthy range. It has decreased from 1.04 (Mar 23) to 0.80, marking a decrease of 0.24.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.80. It has increased from 0.46 (Mar 23) to 0.80, marking an increase of 0.34.
• For Current Ratio (X), as of Mar 24, the value is 1.37. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 23) which recorded 1.37.
• For Quick Ratio (X), as of Mar 24, the value is 0.66. This value is below the healthy minimum of 1. It has increased from 0.65 (Mar 23) to 0.66, marking an increase of 0.01.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.38. This value is below the healthy minimum of 4. It has increased from 1.29 (Mar 23) to 1.38, marking an increase of 0.09.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 1.48. This value is below the healthy minimum of 3. It has decreased from 3.61 (Mar 23) to 1.48, marking a decrease of 2.13.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.08. This value is below the healthy minimum of 3. It has decreased from 1.85 (Mar 23) to 0.08, marking a decrease of 1.77.
• For Enterprise Value (Cr.), as of Mar 24, the value is 2,050.95. It has decreased from 2,685.65 (Mar 23) to 2,050.95, marking a decrease of 634.70.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.27. This value is within the healthy range. It has decreased from 1.60 (Mar 23) to 1.27, marking a decrease of 0.33.
• For EV / EBITDA (X), as of Mar 24, the value is 22.92. This value exceeds the healthy maximum of 15. It has increased from 12.72 (Mar 23) to 22.92, marking an increase of 10.20.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.19 (Mar 23) to 0.92, marking a decrease of 0.27.
• For Price / BV (X), as of Mar 24, the value is 1.83. This value is within the healthy range. It has decreased from 2.66 (Mar 23) to 1.83, marking a decrease of 0.83.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.19 (Mar 23) to 0.92, marking a decrease of 0.27.
• For EarningsYield, as of Mar 24, the value is -0.06. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to -0.06, marking a decrease of 0.08.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness